University College London

Ascension Healthcare to Present Positive Phase 2 Data on Two Haemophilia Programmes at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Fibrinolysis, University College London, Company, Male, 2021 Essex County Council election, Society, Ascension, Bleeding, ASH, Coronavirus Scientific Advisory Board (Turkey), Use, Potency, VIII, XLR8, Haemophilia, Risk, Prevalence, Selective serotonin reuptake inhibitor, Patient, Osteoarthritis, Pharmaceutical industry, Dentistry

The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.

Key Points: 
  • The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.
  • Biresh Roy, Chief Executive Officer at Ascension commented: We are immensely privileged to have been selected to present our successful Phase 2 SelectAte and XLR8 programmes at ASH, a world leader insupporting and promulgating clinical and scientific developments in haematology.
  • This is a large market that is, at present, not served by a safe, convenient, inexpensive prophylactic replacement FVIII treatment.
  • XLR8 is a form of PEGLip administered as an adjuvant to patients who already have some circulating FVIII.

CYENS Centre of Excellence presents at BioJapan / Regenerative Medicine Japan / healthTECH expo in Japan

Retrieved on: 
Wednesday, November 2, 2022
Cyprus University of Technology, Open University, PULSE, Pain, Posture, Muscle, VR, Government, Municipality, Injury, Research, Framework Programmes for Research and Technological Development, University College London, Republic, PSA, Virtual reality, Anxiety, University, Open University of Cyprus, Max Planck Institute for Informatics, Athlete, Association of British HealthTech Industries, Movement, Mental health, Medical device, EU, Informatics

The purpose of this tool is to prevent, diagnose and rehabilitate musculoskeletal disorders, caused by repetitive movements during work.

Key Points: 
  • The purpose of this tool is to prevent, diagnose and rehabilitate musculoskeletal disorders, caused by repetitive movements during work.
  • The biofeedback mirror tool uses motion tracking and electromyography sensors to display full-body musculo-postural feedback that simulates the movement of the user in real-time.
  • "Imagine a mirror showing you what your posture and muscles are doing while you are playing an instrument or exercising.
  • CYENS is funded by the EU's Horizon 2020 and the Government of the Republic of Cyprus.

EQS-News: Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Friday, October 28, 2022
Diamond, Drug discovery, Max Planck Society, Drug development, Villigen, Disease, Gesellschaft mit beschränkter Haftung, Drug design, Probability, GSK, Olaparib, Lists of diseases, Max Planck Institute of Biochemistry, Joint Planning and Development Office, Biology, Science, University College London, Cancer, Gene, Nobel Prize, Genome, Partnership, Pharmaceutical industry, IND, Dodi Protero

Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.

Key Points: 
  • Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.

Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro

Retrieved on: 
Wednesday, October 26, 2022
Consultant, Therapy, Biology, Drug discovery, Doctor of Philosophy, Cancer, Disease, Â, Cell death, Drug resistance, Aberration, Patient, FRSB, Computational biology, Research, UCL, GLOBE, Time, Drug combination, University College London, Pharmaceutical industry, Medical imaging, Medical device, Management, Fine chemical, Fisher, Algorithm

CipherPro is a proprietary suite of algorithms to mine TxPro and other databanks to support oncology drug discovery and development.

Key Points: 
  • CipherPro is a proprietary suite of algorithms to mine TxPro and other databanks to support oncology drug discovery and development.
  • The agreement via UCL Consultants means Promatixs Principal Computational Scientist, Dr Daniel Holdbrook, will work with the Fisher Lab to develop new computational executable cancer models.
  • Professor Fisher, who is on the Promatix advisory board, is internationally renowned for her vision and groundbreaking achievements in this space.
  • We are pleased to work with the Promatix team to accelerate identification of new oncology therapeutic targets and suggest new drug combination treatments.

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Diamond, Lists of diseases, Drug design, GSK, Disease, Science, Nobel Prize, Max Planck Institute of Biochemistry, Drug development, Biology, Villigen, Joint Planning and Development Office, Partnership, Olaparib, Max Planck Society, Probability, University College London, Drug discovery, Gesellschaft mit beschränkter Haftung, GLOBE, Genome, Gene, Cancer, Pharmaceutical industry, IND, Dodi Protero

Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.

Key Points: 
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.
  • We are delighted to support Adrestia in their accelerated drug discovery endeavors for a variety of complex targets to treat genetic diseases, said Dr. Debora Konz Makino, Proteros VP Business Unit Discovery Solutions.

Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, Lists of diseases, Master of Science, Drug design, Diamond Light Source, University of Nottingham, GSK, Therapy, Disease, Hope, Science, Amphisbaena, Nobel Prize, University, Max Planck Institute of Biochemistry, Drug development, Research, Joint Planning and Development Office, Villigen, Astex, Institute, Partnership, Olaparib, Artificial intelligence, Cancer, Gene, Max Planck Society, Probability, University College London, Drug discovery, Atlas, Doctor of Philosophy, Industry, Charles River Laboratories, Gesellschaft mit beschränkter Haftung, Cancer Research UK, Genetics, Genome, Head, GW Pharmaceuticals, Pharmaceutical industry, IND, Chemistry, Dodi Protero, Adrasteia

Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.

Key Points: 
  • Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.
  • He has led or been involved with the delivery of seven drug candidates across a range of target classes.
  • In Jamess most recent position he ran the medicinal chemistry function at Amphista Therapeutics.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new targets for treating intractable genetic diseases.

juli Honored as a Top 50 Technology of the Year by Massachusetts Technology Leadership Council

Retrieved on: 
Thursday, October 13, 2022
Hypertension, Migraine, Tech, Machine learning, Policy, Patient, Depression, Asthma, Bipolar disorder, UCL, Technology, University College London, Health, AI, CEO, Association, Randomized controlled trial, Environment, Chronic pain, Conditional sentence, Health insurance, Pharmaceutical industry

BOSTON, Oct. 13, 2022 /PRNewswire/ -- juli , the AI-powered chronic conditionplatform, has been named a Tech Top 50 honoree by the Massachusetts Technology Leadership Council ( MassTLC ), the region's leading technology association and the premier network for tech executives, entrepreneurs, investors and policy leaders.

Key Points: 
  • BOSTON, Oct. 13, 2022 /PRNewswire/ -- juli , the AI-powered chronic conditionplatform, has been named a Tech Top 50 honoree by the Massachusetts Technology Leadership Council ( MassTLC ), the region's leading technology association and the premier network for tech executives, entrepreneurs, investors and policy leaders.
  • The award recognizes Massachusetts technologies that have made a significant impact during the past year across 11 categories, and juli was recognized in the Healthcare Tech category.
  • "We are thrilled to be recognized by MassTLC for our platform to help manage chronic conditions," said Bettina Hein, juli's CEO and co-Founder.
  • juli engages consumers to power their own health while offering their healthcare providers insights from sub-episodic health data.

abrdn plc Joins Hedera Governing Council, Cementing its Vision for Web3 and Client-centric Fund Management

Retrieved on: 
Thursday, October 6, 2022
WorldPay, LG Electronics, Telegram Open Network, IBM, Efficiency, New Senior Investment Group, DLT, Investment, FIS, Organization, Indian Institute of Technology (BHU) Varanasi, Piper, Twitter, Council, Institute, Nomura Holdings, UCL, Technology, Electronics, IIT, Zain Group, University College London, DLA Piper, ServiceNow, Industry, ABDN, Wipro, Worldpay, Avery Dennison, DLA, Ubisoft, EDF, Hedera helix, Telegraphy, Solution, Standard Bank, Discord, Deutsche Telekom, Cryptocurrency, Financial services, Google, Web3, Hedera, Boeing

EDINBURGH, Scotland, Oct. 6, 2022 /PRNewswire/ -- Investment company abrdn has today joined the Hedera Governing Council as the first buyside finance and asset management company on the Council. abrdn believes that distributed ledger technology (DLT) has the potential to transform structural inefficiencies that exist in the fund management industry. It sees Hedera as the technology of choice for this shift due to its interest in strong governance, operational efficiency, and the environmental sustainability of Hedera's best-in-class energy efficiency.

Key Points: 
  • abrdn believes that distributed ledger technology (DLT) has the potential to transform structural inefficiencies that exist in the fund management industry.
  • abrdn is currently examining future prospects for the tokenization of investment funds, using Hedera, with the aim of listing these on a digital exchange.
  • Hedera's network is capable of cutting through management work and making tokenized money management faster and more cost-efficient, while preserving its security and sustainability.
  • abrdn also sees scope to work with service providers to use Hedera for their other DLT-based services, allowing a fully onchain experience for fund investing.

K2 INTEGRITY ANNOUNCES EXPANSION OF ESG CERTIFICATION SOLUTION

Retrieved on: 
Tuesday, October 4, 2022
Data collection, Solution, Private law, Cayman Islands, Central Bank of Ireland, Maples Group, Carnegie Mellon University, SFDR, U.S. Securities and Exchange Commission, British Virgin Islands, Partnership, Virgin Islands, Capitalism, LinkedIn, Technology, Business development, Intelligence, Industry, Lawyer, Compliance, Omidyar Network, Certification, ESG, Twitter, S&P Global, Central bank, RepRisk, Communication, Cornell University, Ford Foundation, Risk management, Foundation (nonprofit), Machine learning, University College London, Investment, NEW, Risk, University, AI, Strategic partnership, GP, Leading, Lithium, Security (finance), K2, Eupithecia novata

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- K2 Integrity, a leading compliance and risk advisory firm, today announced strategic partnerships with RepRisk, a leading ESG data science firm combining AI and machine learning together with human intelligence to identify ESG risks, and Novata, the leading ESG data management platform built for the private markets, to bolster K2 Integrity's new ESG fund certification solution.

Key Points: 
  • K2 Integrity and the Maples Group formed their partnership to launch a first-of-its-kind ESG certification earlier this year .
  • K2 Integrity's new ESG certification solution builds on the firm's longstanding reputation for assisting clients with all forms of risk management and regulation compliance.
  • Neelam Sharma, Chief Business Development and ESG Officer of K2 Integrity, added: "ESG compliance is a priority, we have successfully been able to respond to this industry need and launch an end-to-end ESG solution.
  • Together, the partnerships will allow K2 Integrity to customize the solution to offer different certification types that align with regional ESG regulations.

K2 INTEGRITY ANNOUNCES EXPANSION OF ESG CERTIFICATION SOLUTION

Retrieved on: 
Tuesday, October 4, 2022
Data collection, Solution, Private law, Cayman Islands, Central Bank of Ireland, Maples Group, Carnegie Mellon University, SFDR, U.S. Securities and Exchange Commission, British Virgin Islands, Partnership, Virgin Islands, Capitalism, LinkedIn, Technology, Business development, Intelligence, Industry, Lawyer, Compliance, Omidyar Network, Certification, ESG, Twitter, S&P Global, Central bank, RepRisk, Communication, Cornell University, Ford Foundation, Risk management, Foundation (nonprofit), Machine learning, University College London, Investment, NEW, Risk, University, AI, Strategic partnership, GP, Leading, Lithium, Security (finance), K2, Eupithecia novata

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- K2 Integrity, a leading compliance and risk advisory firm, today announced strategic partnerships with RepRisk, a leading ESG data science firm combining AI and machine learning together with human intelligence to identify ESG risks, and Novata, the leading ESG data management platform built for the private markets, to bolster K2 Integrity's new ESG fund certification solution.

Key Points: 
  • K2 Integrity and the Maples Group formed their partnership to launch a first-of-its-kind ESG certification earlier this year .
  • K2 Integrity's new ESG certification solution builds on the firm's longstanding reputation for assisting clients with all forms of risk management and regulation compliance.
  • Neelam Sharma, Chief Business Development and ESG Officer of K2 Integrity, added: "ESG compliance is a priority, we have successfully been able to respond to this industry need and launch an end-to-end ESG solution.
  • Together, the partnerships will allow K2 Integrity to customize the solution to offer different certification types that align with regional ESG regulations.